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Immunotherapy for Food Allergy
Kazuyuki Kurihara1
ABSTRACT
Although the current standard care for patients with food allergy is based on avoidance of the trigger foods with
hope of possible gain of tolerance, increasing number of studies have shown that oral immunotherapy is a
promising approach. Understanding the transcutaneous sensitization and oral immune tolerance to food anti-
gens has shifted focus of treatment and prevention. However, more studies are warranted to elucidate the un-
derlying mechanisms and to clarify the indication criteria to which type of patients this therapy should be ap-
plied. Easy and uncontrolled use of elimination diets for atopic dermatitis might have increased and exacer-
bated food allergy, and thorough innovation of our whole concept for food allergy is now required.
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INTRODUCTION
My task is a review on the immunotherapy for food
allergy in a special issue on the immunotherapy for
allergic diseases. The immunotherapy for food al-
lergy may be somewhat different from the immuno-
therapy for other allergic diseases, because it is not
recognized widely and the practical methods are not
established yet, although as a matter of fact there is a
fairly long history for oral immunotherapy for food al-
lergy. The number of successful reports of immuno-
therapy (tolerance induction) for food allergy has
been increasing in recent years, and the enormous
hope for positive and radical treatment of food allergy
is coming in sight. Furthermore, the understanding
of oral immune tolerance and the results of some epi-
demiological studies are seriously demanding us
thorough reconsideration about the pathogenesis of
food allergy and our current policy to prevent or man-
age food allergy.
IMMUNOTHERAPY (TOLERANCE INDUC-
TION) FOR FOOD ALLERGY
INJECTION IMMUNOTHERAPY
Although there are rare successful reports of injec-
tion immunotherapy on fish allergy1 and on peanut al-
lergy,2 studies in 1990s indicated that subcutaneous
injection immunotherapy for peanut allergy was not
recommended because of unacceptably high rate of
adverse systemic reactions.3 On the contrary, increas-
ing number of reports on oral immunotherapy for
food allergy has been being published recently.
TERMINOLOGY OF ORAL IMMUNOTHERAPY
FOR FOOD ALLERGY
Terminology for the oral immunotherapy for food al-
lergy based on an escalating dosage of orally in-
gested foods or food protein has not been unified.
Copying after the examples of other immunotherapy,
such as subcutaneous immunotherapy (SCIT) or sub-
lingual immunotherapy (SLIT), the term of oral im-
munotherapy should be appropriate. Though some
authors have expressed their methods as oral desen-
sitization or oral hyposensitization, these terms
should be closely associated with the functioning
mechanisms, then these are suitable if the effect of
these treatments to improve sensitization, in other
words to reduce or delete specific IgE to the foods
used for the treatment, becomes secure. The purpose
of these treatments is to enable patients of food al-
lergy to ingest offending foods to some extent with-
out obvious adverse reactions, and I myself call our
own method specific oral tolerance induction (SOTI).
THE ORIGINATON
Oral immunotherapy for food allergy started to get a
wide range of attention only for the past few years.
The number of publication identified by searching
PubMed with the key words of “food allergy & immu-
notherapy” or “food allergy & oral tolerance” started
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Fig. 1 The numbers of published papers on immunotherapy 
or oral tolerance for food alergy. The numbers of published 
papers found by searching PubMed with keywords of “food 
alergy & immunotherapy” or “food alergy & oral tolerance” 
since 1990 are shown. † Searched on September 1, 2009.
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Table 1 Classification of oral immunotherapy (tolerance in-
duction) for food alergy
Rush(days-weeks)
Tempo Slow(months-years)
Rush → Slow
Oral (ingestion)
Route Sublingual
Sublingual + oral
In hospital
Seting At home (and outpatient clinic)
In hospital → At home
to increase after 2002 as indicated in Figure 1. How-
ever, Brown4 introduced a paper written by Scho-
field5 published in 1908 as a very old successful case
of oral immunotherapy for egg allergy.
The title of Schofield’s paper is “A case of egg poi-
soning”, not “A case of egg allergy”, but we have to
remember that it was 1906 that von Pirquet coined
the term “allergy” de novo. And you will realize easily
that the case of a 13-year old boy described there was
no doubt a sample of typical severe egg allergy.
Schofield gave the boy a pill daily, which contained
gradually increasing amounts of raw egg starting
from 110,000th of an egg, and the boy eventually
could eat a whole egg 8 months after.
THE PROGRESS
Thereafter, the experiences of the oral immunother-
apy for food allergy had been reported sporadically
from European countries such as Spain, Italy, Ger-
man, et al., but they seemed to be treated as rather
heresy, and did not arrest much attention. The qual-
ity of reports or studies varied greatly, and some
were just case reports of small number, and each re-
port utilized individual protocols based on their own
experiences. It is very interesting to note that Mono-
graphs in Allergy featured a procon debate on oral
desensitization for cow’s milk allergy in 1996,6,7 when
the journal had been discontinued. In 1990s, a few
clinical reports on oral immunotherapy for food al-
lergy appeared every year, sporadically or repeatedly
by some groups, and the quality of the study became
better, and got broader attention gradually. Enrique
et al.8 reported the effectiveness of sublingual immu-
notherapy for hazelnut allergy in a double-blind fash-
ion, and Longo et al.9 reported the one-year follow up
of oral tolerance induction for severe milk allergy, in
which they showed high-rate acquisition of tolerance
in active group and virtually no improvement in avoid-
ance group. Then, Skripak et al.10 clearly proved that
deliberate oral intake of cow’s milk protein for several
months was safe and efficacious in tolerizing children
with cow’s milk allergy in a double-blind, placebo-
controlled fashion. And Martorell et al.11 and Staden
et al.12 reported the successful results of rush oral im-
munotherapy carried out during only 3-7 days.
The protocols of the oral immunotherapy reported
so far are classified as Table 1.
EVALUATION OF THE ORAL IMMUNOTHERAPY
FOR FOOD ALLERGY
At the present day, though there are various opinions
about the oral immunotherapy for food allergy, af-
firmative ones are increasing. Niggemann et al.13
summarized in a review article in 2006 that the body
of scientific evidence concerning specific oral toler-
ance induction was still rather poor, and before SOTI
could be recommended for the daily praxis, more
studies were warranted to clarify whether certain pa-
tients might profit from SOTI and to understand the
underlying mechanism. Then, however, they pub-
lished new data of SOTI under the protocols per-
formed at home on a daily basis during a median of
21 months in 2007,14 and also under the rush proto-
cols performed in hospital, reaching the goal during 3
to 7 days in 2008.12 Beyer & Wahn15 in 2008 con-
ceded that several studies had shown that oral immu-
notherapy was a promising approach, especially in pa-
tients with severe and persistent food allergy, and
that side effects were frequent but seemed controlla-
ble. But they concluded that treatment protocols had
been performed in highly supervised research set-
tings, and until more experience was gained from
larger long-term studies, oral immunotherapy should
not be tried in clinical practice settings. Shaker&
Woodmansee16 introduced a new concept about the
timing of weaning and the introduction of solid foods,
explaining that avoidance of highly allergenic foods
beyond 4-6 months might not be effective at prevent-
ing the development of food allergy in most children,
and the effect of specific early introduction of aller-
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Table 2 Rush SOTI for egg alergy: Background of subjects and the results. Six new cases are added to the original data 
cited as reference 20.
Symptoms during 
treatment
Days of rush 
SOTI †
Threshold 
ComplicationsAge of last anaphylaxisby cooked eggAgeSex
Subject 
number after (g)before (g)
WH, UR, AP18 (13)>600.360BA, AD9y2m 9y8mF001
UR13 (9)>600.012BA, AD, AR8y0m 8y5mM002
AP9 (7)>600.296BA, AD, AR11y3m 12y0mM003
WH, UR10 (8)>600.200BA, AD, AC6y9m 7y2mF004
AP, DI15 (11)>600.088BA, AD 8y10m 9y4mM005
AP, DI11 (9)>600.104BA, AD10y10m11y4mM006
WH, UR, AP15 (10)>600.144AD, AR, AC10y10m11y3mM007
UR, AP10 (8)>600.752AD11y0m 11y2mF008
WH, UR, DI14 (9)>600.752BA, AD, AR6y4m 6y9mM009
WH, UR15 (11)>600.011BA7y6m 7y8mM010
WH, UR15 (11)>600.030BA, AD3y0m 7y9mF011
WH, UR, AP, DI15 (11)>600.013BA3y2m 6y9mM012
14.5 (9.5)>60(cooked egg)
0.124
(raw EW) 8y7mMedian
SOTI, specific oral tolerance induction; EW, egg white; BA, bronchial asthma; AD, atopic dermatitis; AR, alergic rhinitis; AC, alergic con
junctivitis; WH, wheezing; UR, urticaria; AP, abdominal pain; DI, diarhea.
† Figures in parenthesis do not include the days staying at home without increase in the dose of egg.
genic foods was being investigated. At the same time,
they expressed their negative attitude about oral im-
munotherapy, saying that oral immunotherapy was
under investigation but might be limited in future use
by several factors, including a significant rate of aller-
gic reactions.
There are more affirmative and positive opinions.
Burks et al.17 asserted that increased understanding
of the mechanisms involved in tolerance had shifted
focus of treatment and prevention toward inducing
tolerance, although the current standard of care for
patients with food allergies was based on avoidance
of the trigger, and continued that data from early-
phase clinical trials suggested both sublingual and
oral immunotherapy were effective in reducing sensi-
tivity to allergens. And Barbi et al.18 said that “We hy-
pothesize that widespread and uncontrolled use of
elimination diets for atopic dermatitis may have
played a role in the increase of allergy and anaphy-
laxis. Specific oral tolerance induction may be a possi-
ble therapeutic strategy.” Patriarca has been one of
the pioneers of this field, and he and his colleagues
reported clinical data repeatedly, and wound up their
recent review article19 by writing that “The only etio-
logic treatment of food allergy is specific desensitiza-
tion. Sublingual-oral-specific desensitization has been
used by our group for the treatment of food-allergic
patients with a high percentage of success.”
OUR EXPERIENCES
We consider the injection immunotherapy for pollen
allergy or nasal allergy is a very important and rare
radical treatment, and we are carrying it out in a rush
fashion in which patients receive allergen shots sev-
eral times a day in hospital.20 And by getting the
knowledge concerning the oral immune tolerance,
we began to think of rush immunotherapy for food al-
lergy through oral route instead of injection. After the
certification by the institutional ethical committee, we
started the first trial of rush specific oral tolerance in-
duction (rush SOTI) in September, 2007. The report
about our first 6 cases with severe egg allergy treated
by rush SOTI and the follow up to 1 year has been ac-
cepted by Allergology International, and is coming out
soon.21
Adding 6 cases to the report of first 6 cases in-
cluded in the previous report,21 the summary of 12
cases with anaphylaxis-type severe egg allergy
treated by rush SOTI is shown in Table 2 and in Fig-
ure 2. All subjects, whose threshold to raw egg white
was 0.124 g in median (0.011-0.752 g), acquired oral
tolerance to more than one whole cooked-egg (60 g),
and it took only 14.5 days (9-18 days). In this proce-
dure, material of egg was changed from raw egg-
white powder to cooked egg when the dose reached
8 g because of the taste and the convenience in daily
life. None experienced any serious reaction requiring
adrenaline injection. Among 640 dosing of egg mate-
rials during rush SOTI for these 12 subjects, we expe-
rienced 118 very mild reactions (itch of mouth or
throat, mild skin rash), 36 mild reactions (wide range
of skin rash, transient complaints of digestive or res-
piratory system), and 2 moderate reactions (skin rash
across the whole body, prolonged or repeated diges-
tive system, or mild dyspnea), but no case of severe
reactions including shock. The medication used to re-
lieve these adverse reactions were 33 oral antihista-
mines, 15 inhalations of salbutamol, 1 oral prednis-
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Fig. 2 The individual process of rush SOTI for egg alergy to reach a whole egg. The ab
scissa expresses the days after starting rush SOTI. The ordinate expresses the single 
doses of egg ploted in logarithmic scale. Rush SOTI was started with powdered raw egg 
white, and when the dose reached 8 g, it was changed to cooked egg. Six new cases are 
added to the original figure which has been shown in the reference 21.
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lolone, and 2 injections of antihistamine. From the
analysis of the first 6 cases, specific IgE to egg white
or ovomucoid tended to increase at the end of rush
SOTI, thereafter tended to decrease, and decreased
significantly after 12 months. Egg white-specific IgG4
levels increased significantly only after 12 months. At
the moment, the immunological mechanisms occur-
ring during rush SOTI are not clear. Although further
studies involving a large group of patients and thor-
ough analyses of the mechanisms are needed, we
consider that rush SOTI is a promising maneuver
that would replace allergen avoidance as the therapy
for food allergy.
We do not consider that the rush method is supe-
rior to the procedure carried out slowly at home,
spending several months to reach the goal, that is
slow SOTI. Actually, we are treating much more pa-
tients with slow SOTI than with rush SOTI. We as-
sume the food challenge test as a step to evaluate the
threshold to tell them the dose to start ingestion of
the food safely, not to just decree the absolute elimi-
nation to them when the result is positive.
ORAL IMMUNE TOLERANCE
One of the theoretical bases of oral immunotherapy is
oral immune tolerance, which is not a new idea at all,
and has been a subject of research in immunology for
nearly 100 years. Already in 1911, Wells & Osborne22
clearly showed that guinea pigs fed on corn did not
come up with anaphylactic responses when sensi-
tized and challenged by a corn protein. Vaz et al.23
showed that one dose of 20 mg OVA administered
orally 7 or 14 days before parenteral immunization in-
hibited the response of IgE and IgG almost com-
pletely. Ngan & Kind24 found that the inhibitory ef-
fect of OVA administered orally was maintained at
the dose of only 100 μgmouse. Peng et al.25 investi-
gated the immunological consequences of feeding a
protein antigen to previously immunized animals, and
found that oral tolerance depended on the immune
status of the animal and was controlled by antigen
dose, time and frequency of feeding.
Now, some mechanisms of oral immune tolerance
have been elucidated from investigation of animal
model. High-dose tolerance is mediated by lympho-
cyte anergy or clonal deletion, and low-dose tolerance
is mediated by some kinds of regulatory T cells and
some cytokines, such as IL-10 and TGF-β.26 More
mechanistic studies are mandatory to test whether
these phenomena are similar in human subjects and
to resolve the process predisposing some individuals
to food allergy.
PREVENTION OF FOOD ALLERGY
Elimination of highly allergic foods is plausible to pre-
vent the development of food allergy, and many trials
of preventive elimination for high-risk babies were ac-
tually performed, most of them turning out failure or
limited success. Concerning the timing of solid food
introduction, the delay does not seem to prevent the
development of food allergy, but may enhance sensiti-
zation to some foods.27,28 Anderson et al.29stated that
currently-available research suggested that introduc-
ing solids at 4-6 months might result in the lowest al-
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Allergology International Vol 59, No1, 2010 www.jsaweb.jp 13
lergy risk, and that the recommended duration of ex-
clusive breastfeeding and age of introduction of sol-
ids were confirmed to be 6 months, but no later.
American Academy of Pediatrics (AAP) had recom-
mended in 2000 for high-risk infants not to introduce
solid foods until 6 months of age, with dairy products
delayed until 1 year, egg until 2 years, and peanuts,
nuts, and fish until 3 years of age, without showing
secure evidences.30 AAP made a revised statement in
2008 to replace the former recommendation,31 and
they recommended exclusive breastfeeding for at
least 4 months for infants at high risk of developing
atopic disease, but said that there is no current con-
vincing evidence that delaying solid food introduction
beyond 4-6 months of age has a significant protective
effect on the development of atopic disease, including
fish, eggs, and foods containing peanut protein. Fol-
lowing this, an interesting report by Du Toit et al.32
came out. They demonstrated that Jewish children in
the UK had a prevalence of peanut allergy that was
10-fold higher than that in Israel (1.85% vs 0.17%, P <
0.001), and Israeli infants consumed peanut in high
quantities in the first year of life, whereas UK infants
avoided peanuts. They raised an important proposi-
tion that whether early introduction of peanut during
infancy, rather than avoidance, would prevent the de-
velopment of peanut allergy. Their data might be a
good example of oral immune tolerance in human
model.
I want to refer to new topics on atopic dermatitis.
Even though the close relation between the sensitiza-
tion to foods and atopic eczema is obvious, this does
not necessarily mean the causative importance of
food allergy for atopic eczema. The pathogenesis of
atopic dermatitis is not fully clarified, but new theory
was brought to our knowledge recently. Elias et al.33
assessed evidences that inflammation in atopic der-
matitis results from inherited and acquired insults to
the barrier abnormality of skin, including loss-of-
function mutation in the gene encoding filaggrin. And
further, Lack34 proposed “Dual-allergen- exposure hy-
pothesis for pathogenesis for food allergy”, suggest-
ing that sensitization to food allergen occurs through
environmental exposure through the skin and that
oral consumption of food allergen induces oral toler-
ance.
CONCLUSION
Probably, we are standing at a very important turning
point concerning the management of food allergy.
Understanding of the transcutaneous sensitization
and oral immunotolerance to food antigens are pre-
cipitating thorough innovation of our whole concept
for the pathogenesis of food allergy. Oral immuno-
therapy or tolerance induction for food allergy by de-
liberate oral intake of foods which cause allergic reac-
tions seems a promising approach which liberates pa-
tients from persistent anxious of sudden and serious
symptoms and endless effort to avoid a trace of cer-
tain foods in daily life. This concept is quite different
from the most basic principle of the management of
allergic diseases which says “To reduce or avoid the
exposure to relevant allergens.” The body of scien-
tific evidences for the therapy is still poor, and the
therapy naturally possesses the risk of inducing aller-
gic reactions. More studies are warranted to eluci-
date the underlying mechanisms and to establish
safer and securer practical methods urgently.
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